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might indicate a functional relevance of these cells in the re-
spective entities. Since increased numbers of PD-1+ cells 
outside GC are observed in various LA, this finding might not 
be entirely specific for pattern I AITL. 
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 Introduction 
 Programmed death-1 (PD-1) is a member of the CD28 
costimulatory receptor superfamily. It is expressed on a 
subset of thymocytes and is upregulated on activated T, 
B and myeloid cells. Dorfman et al.  [1] found that PD-1 is 
specifically expressed by germinal center (GC)-associat-
ed T cells in reactive lymphoid tissue as well as by tumor 
cells in angioimmunoblastic T-cell lymphoma (AITL).
 PD-1 inhibits T-cell activity via a negative signal to T 
cells in conjunction with signaling through the T-cell re-
ceptor. Recent studies indicate that PD-1 functions as a 
negative regulator of the immune system and is impor-
tant in peripheral tolerance  [2] . There are at least two li-
gands for PD-1, PD-L1 and PD-L2. PD-L-PD-1 interac-
tions lead to cell cycle arrest in G 0 /G 1 but do not increase 
cell death. PD-L1 engagement of PD-1 on T cells inhibits 
activation of these cells. Engagement of PD-1 by PD-L2 
dramatically inhibits T-cell receptor-mediated prolifera-
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 Abstract 
 Objectives: Programmed death-1 (PD-1) is physiologically 
expressed by germinal center (GC)-associated helper T cells. 
It has been proposed that an increase in PD-1+ cells outside 
GC could indicate pattern I angioimmunoblastic T-cell lym-
phoma (AITL).  Methods: We studied the distribution of PD-
1+ cells in reactive lymphadenopathies (LA), including HIV-
associated and dermatopathic LA (n = 5, each), Castleman 
(n = 3), Kikuchi (n = 2) and Rosai-Dorfman diseases (n = 1), 
sarcoidoses (n = 7) and follicular hyperplasias (n = 8).  Results: 
The highest concentrations of PD-1+ cells in GC were found 
in Castleman and Rosai-Dorfman diseases (mean 57 and 
50% of total cells, respectively), and the lowest in HIV-associ-
ated LA (mean 6%). The highest proportions in paracortices 
were found in Castleman disease, and in HIV-associated and 
dermatopathic LA (mean 7, 3 and 2%, respectively). PD-1+ 
cells predominated in the pale zones of GC in follicular hy-
perplasia. In HIV-associated LA, PD-1+ cells showed marked 
marginalization in the GC. No paracortical PD-1+ cells were 
found in sarcoidoses and Rosai-Dorfman disease.  Conclu-
sions: The varying distribution of PD-1+ cells in defined LA 
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tion and cytokine production by CD4+ cells  [3] . It has 
been shown that PD-1 is selectively upregulated by ex-
hausted T cells during chronic viral infection such as 
HIV. Blockade of PD-1-related pathways restores CD8+ 
T-cell functions and reduces viral load  [4] .
 It has been proposed that an increase in PD-1+ cells 
outside GC could be a precursor lesion of AITL  [5, 6] . The 
aim of our study was to determine the distribution of PD-
1+ cells, particularly their appearance outside GC, in var-
ious reactive lymphadenopathies (LA).
 Material and Methods 
 Thirty-one samples of various LA were collected from the ar-
chives of the Institute of Pathology at the University Hospital of 
Basel. All were reevaluated and the initial diagnosis was con-
firmed: dermatopathic LA (n = 5), Castleman disease of the hya-
line-vascular type, all HIV negative (n = 3), Kikuchi disease (n = 
2), Rosai-Dorfman disease (n = 1), HIV-associated LA (n = 5), sar-
coidoses (n = 7) and follicular hyperplasias (n = 8).
 Immunohistochemistry 
 Immunohistochemical staining of formalin-fixed and paraf-
fin-embedded tissue was performed. Slides were stained manu-
ally. Heat-induced (autoclave) antigen retrieval in citrate buffer 
(pH 6.0) for 10 min at 120 ° C was performed and the streptavidin-
biotin-peroxidase detection technique was applied with amino-
ethylcarbazole  as  chromogen.  The  primary  goat   anti-human  
PD-1 antibody (AF 1086; R & D Systems, Germany) was diluted 
1: 40 in a 1% solution of bovine serum albumin in PBS (pH 7.4) and 
the slides were incubated overnight at 4 ° C. The percentage of PD-
1+ cells in relation to all background cells in different lymph node 
areas was determined considering at least 5 microscopic fields 
(5  ! 1.33 mm 2 ) at 200-fold magnification. Scoring was per-
formed on a double-headed microscope by two of us (S.M. and 
A.T.). Reproducibility was assessed by rescoring of the samples by 
one of us (A.T.) and estimated by interclass correlation coeffi-
cients, using reliability analysis (Cronbach’s   ).
 Results 
 PD-1+ cell quantization was reproducible (average in-
terobservation correlation coefficient 0.92), being excel-
lent (  = 1) in samples with fewer PD-1+ cells, e.g. sar-
coidoses, Kikuchi and Rosai-Dorfman diseases, and good 
(  = 0.84) in HIV-associated and dermatopathic LA. The 
distribution of PD-1+ cells varied considerably between 
the different reactive LA ( table 1 ;  fig. 1 ). The highest per-
centages of PD-1+ cells in GC were found in Castleman 
and Rosai-Dorfman disease (mean 57 and 50% of total 
cells, respectively), and the lowest percentage in HIV-as-
sociated LA (mean 6%). The highest percentage in para-
cortices near the mantle zones were found in Castleman 
disease, and HIV-associated and dermatopathic LA 
(mean 7, 3 and 2%, respectively). PD-1+ cells were located 
between monocytoid B cells in hyperplastic marginal 
zones, between Langerhans’ cells in dermatopathic LA 
and in the pale GC zones in follicular hyperplasia. In 
HIV-associated LA, PD-1+ cells showed a marked mar-
ginalization in GC. No PD-1+ cells were found in the 
paracortices of lymph nodes with sarcoidosis and Rosai-
Dorfman disease and in the necrosis zones of Kikuchi 
disease.
 Discussion 
 In our study, we demonstrate varying distribution of 
PD-1+ cells in defined LA. Clusters of PD-1+ neoplastic 
cells in perifollicular areas and around high endothelial 
venules in the expanded paracortex of lymph nodes have 
been proposed as a diagnostic criterion for pattern I AITL 
 [1, 5, 6] . However, since markedly increased numbers of 
PD-1+ cells are also found in the paracortex of lymph 
Table 1. Distribution of PD-1+ cells in reactive LA
Disease Proportion of PD-1+ cells, % Remark
GC mantle
zones
paracortex
Castleman disease 57820 10817 7811
Dermatopathic LA 2585 180.8 282 scattered between monocytoid cells
Follicular hyperplasia 22821 182 182 abundant in pale zones of GC
HIV-associated LA 684 783 381 marked marginalization in GC
Kikuchi disease 2384 686 0.380.4 absent in necrosis zones
Rosai-Dorfman disease 50 2 0
Sarcoidosis 32814 284 0
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nodes with Castleman disease, and HIV-associated and 
dermatopathic LA, this finding should not be regarded as 
absolutely specific for pattern I AITL and these three con-
ditions might be of relevance to be considered in the dif-
ferential diagnosis. Beyond presence of PD-1+ cell clus-
ters outside GC, the diagnosis of pattern I AITL should 
be corroborated, as suggested by Rodriguez-Justo et al. 
 [6] , by the typical morphological appearance and pres-
ence of Epstein-Barr virus-infected B (immuno)blasts. 
Since Castleman disease and AITL are accompanied by 
immune control deregulation  [7, 8] , the increased num-
bers of extrafollicular PD-1+ cells in the former, analo-
gously to the neoplastic PD-1+ cells of AITL, might be of 
functional relevance in that instance.
 In HIV-associated LA, the number of PD-1+ cells in 
GC was low, with a marked marginalization beneath the 
mantle zones. Recent data show that PD-1 is significant-
ly upregulated on killer T cells that recognize HIV anti-
gens in the peripheral blood of HIV-infected patients. 
This seems to exhaust T cells, which no longer perform 
vital functions to control viral infection  [9] . While the 
proportion of killer T cells expressing PD-1 is markedly 
increased in the peripheral blood of HIV-infected pa-
tients, depletion was noted inside the GC and distinct 
a b c
d e f
g
 Fig. 1.  a PD-1+ cells in a hyperplastic GC of follicular hyperplasia. Note the abundance 
of PD-1+ cells in the pale zone.  ! 100.  b PD-1+ cells in a typical small involuting GC of 
hyaline-vascular Castleman disease. Note the persistence of PD-1+ cells despite GC B-
cell depletion, and their increased numbers in mantle zones and the paracortices near 
the mantle zones.  ! 160.  c Marked depletion inside and marginalization of PD-1+ cells 
beneath the mantle zones of hyperplastic GC of HIV-associated LA type A.  ! 80.  d In-
creased numbers of PD-1+ cells between monocytoid cells in hyperplastic marginal 
zones and between Langerhans cells in dermatopathic LA.  ! 100. No PD-1+ cells in
the paracortex of lymph nodes with Rosai-Dorfman disease ( e ), in necrotic zones of 
Kikuchi disease ( f ) and in sarcoidosis ( g ). Note retained PD-1+ cells in regressed GC. 
 ! 100. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
3/
20
17
 4
:3
5:
12
 P
M
 PD-1+ Lymphocytes in Reactive 
Lymphadenopathies 
Pathobiology 2010;77:24–27 27
follicular marginalization beneath the mantle zones of 
the PD-1+ T-follicular helper cells in HIV-associated LA. 
The functional importance of these PD-1+ cell redistri-
bution patterns, though likely being of relevance, e.g. for 
abnormal B-cell function in HIV infection  [10] , remains 
to be elucidated.
 While there is a general increase in the CD4+/CD8+ 
ratio in lymph nodes in sarcoidosis, this increase does not 
apply to the PD-1+ (CD4+) T cells in the T-cell zones. 
Since PD-1+ T cells have an inhibitory effect on other T 
cells, this lacking increase in PD-1+ cells in the paracor-
tices could be of relevance for the expansion of other 
CD4+ T cells, e.g. in granuloma formation  [11] .
 To summarize, the varying distribution of PD-1+ cells 
in defined LA could indicate their functional relevance 
in the respective entities. Since increased numbers of
PD-1+ cells outside GC are also found in various LA, this 
finding is not entirely specific for pattern I AITL. 
 References 
 1 Dorfman DM, Brown JA, Shahsafaei A, Free-
man GJ: Programmed death-1 (PD-1) is a 
marker of germinal center-associated T cells 
and angioimmunoblastic T-cell lymphoma. 
Am J Surg Pathol 2006; 30: 802–810. 
 2 Probst HC, McCoy K, Okazaki T, Honjo T, 
van den Broek M: Resting dendritic cells
induce peripheral CD8+ T cell tolerance 
through PD-1 and CTLA-4. Nat Immunol 
2005; 6: 280–286. 
 3 Latchman Y, Wood CR, Chernova T, Chaud-
hary D, Borde M, Chernova I, Iwai Y, Long 
AJ, Brown JA, Nunes R, Greenfield EA, 
Bourque K, Boussiotis VA, Carter LL, Car-
reno BM, Malenkovich N, Nishimura H, 
Okazaki T, Honjo T, Sharpe AH, Freeman 
GJ: PD-L2 is a second ligand for PD-1 and 
inhibits T cell activation. Nat Immunol 2001; 
 2: 261–268. 
 4 Barber DL, Wherry EJ, Masopust D, Zhu B, 
Allison JP, Sharpe AH, Freeman GJ, Ahmed 
R: Restoring function in exhausted CD8 T 
cells during chronic viral infection. Nature 
2006; 439: 682–687. 
 5 Roncador G, García Verdes-Montenegro JF, 
Tedoldi S, Paterson JC, Klapper W, Ballabio 
E, Maestre L, Pileri S, Hansmann ML, Piris 
MA, Mason DY, Marafioti T: Expression of 
two markers of germinal center T cells (SAP 
and PD-1) in angioimmunoblastic T-cell 
lymphoma. Haematologica 2007; 92: 1059–
1066. 
 6 Rodriguez-Justo M, Attygalle AD, Munson 
P, Roncador G, Marafioti T, Piris MA: An-
gioimmunoblastic T-cell lymphoma with 
hyperplastic germinal centres: a neoplasia 
with origin in the outer zone of the germinal 
centre? Clinicopathological and immuno-
histochemical study of 10 cases with follicu-
lar T-cell markers. Mod Pathol 2009; 22: 753–
761. 
 7 Shahidi H, Myers JL, Kvale PA: Castleman’s 
disease. Mayo Clin Proc 1995; 70: 969–977. 
 8 Casper C: The aetiology and management of 
Castleman disease at 50 years: translating 
pathophysiology to patient care. Br J Haema-
tol 2005; 129: 3–17. 
 9 Rowland-Jones S, Dong T: HIV: tired T cells 
turn around. Nature 2006; 443: 282–283. 
 10 De Milito A: B lymphocyte dysfunctions in 
HIV infection. Curr HIV Res 2004; 2: 11–21. 
 11 Grunewald J, Eklund A: Role of CD4+ T cells 
in sarcoidosis. Proc Am Thorac Soc 2007; 4: 
 461–464. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
3/
20
17
 4
:3
5:
12
 P
M
